|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ISLR |
Gene summary for ISLR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ISLR | Gene ID | 3671 |
| Gene name | immunoglobulin superfamily containing leucine rich repeat | |
| Gene Alias | HsT17563 | |
| Cytomap | 15q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | A0A146E5L3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3671 | ISLR | AEH-subject1 | Human | Endometrium | AEH | 2.01e-45 | -8.73e-01 | -0.3059 |
| 3671 | ISLR | AEH-subject2 | Human | Endometrium | AEH | 9.10e-43 | -8.72e-01 | -0.2525 |
| 3671 | ISLR | AEH-subject3 | Human | Endometrium | AEH | 1.07e-43 | -8.58e-01 | -0.2576 |
| 3671 | ISLR | AEH-subject4 | Human | Endometrium | AEH | 8.82e-25 | -8.00e-01 | -0.2657 |
| 3671 | ISLR | AEH-subject5 | Human | Endometrium | AEH | 2.97e-52 | -8.93e-01 | -0.2953 |
| 3671 | ISLR | EEC-subject1 | Human | Endometrium | EEC | 6.49e-49 | -8.90e-01 | -0.2682 |
| 3671 | ISLR | EEC-subject2 | Human | Endometrium | EEC | 1.25e-56 | -9.02e-01 | -0.2607 |
| 3671 | ISLR | EEC-subject3 | Human | Endometrium | EEC | 2.03e-50 | -8.57e-01 | -0.2525 |
| 3671 | ISLR | EEC-subject4 | Human | Endometrium | EEC | 1.99e-44 | -8.46e-01 | -0.2571 |
| 3671 | ISLR | EEC-subject5 | Human | Endometrium | EEC | 5.18e-51 | -8.77e-01 | -0.249 |
| 3671 | ISLR | GSM5276934 | Human | Endometrium | EEC | 1.24e-42 | -8.46e-01 | -0.0913 |
| 3671 | ISLR | GSM5276935 | Human | Endometrium | EEC | 1.25e-56 | -8.98e-01 | -0.123 |
| 3671 | ISLR | GSM5276937 | Human | Endometrium | EEC | 2.24e-34 | -8.44e-01 | -0.0897 |
| 3671 | ISLR | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 8.13e-38 | -8.89e-01 | -0.1869 |
| 3671 | ISLR | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 5.46e-37 | -9.02e-01 | -0.1875 |
| 3671 | ISLR | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.05e-39 | -8.88e-01 | -0.1883 |
| 3671 | ISLR | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.19e-55 | -8.91e-01 | -0.1934 |
| 3671 | ISLR | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 4.01e-57 | -9.02e-01 | -0.1917 |
| 3671 | ISLR | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 7.45e-54 | -9.02e-01 | -0.1916 |
| 3671 | ISLR | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 8.27e-05 | -3.83e-01 | -0.1269 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ISLR | SNV | Missense_Mutation | rs146746279 | c.593N>T | p.Thr198Met | p.T198M | O14498 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ISLR | SNV | Missense_Mutation | novel | c.854N>C | p.Val285Ala | p.V285A | O14498 | protein_coding | tolerated(0.16) | benign(0.1) | TCGA-C8-A130-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ISLR | SNV | Missense_Mutation | c.1097N>A | p.Gly366Glu | p.G366E | O14498 | protein_coding | deleterious(0.01) | benign(0.086) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ISLR | SNV | Missense_Mutation | novel | c.387N>A | p.Met129Ile | p.M129I | O14498 | protein_coding | deleterious(0) | possibly_damaging(0.589) | TCGA-OL-A5DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ISLR | insertion | Nonsense_Mutation | novel | c.847_848insACCAAGGGTCCCCATCTCAGGCCTGAGCCCAATTTAGAGGAGG | p.Pro283HisfsTer9 | p.P283Hfs*9 | O14498 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ISLR | SNV | Missense_Mutation | c.128C>T | p.Ser43Phe | p.S43F | O14498 | protein_coding | deleterious(0.03) | benign(0.054) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ISLR | SNV | Missense_Mutation | rs527446512 | c.487G>A | p.Glu163Lys | p.E163K | O14498 | protein_coding | deleterious(0.05) | possibly_damaging(0.503) | TCGA-MU-A8JM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ISLR | SNV | Missense_Mutation | novel | c.49N>G | p.Gln17Glu | p.Q17E | O14498 | protein_coding | tolerated(0.98) | benign(0.007) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| ISLR | SNV | Missense_Mutation | rs199636609 | c.263N>T | p.Thr88Met | p.T88M | O14498 | protein_coding | deleterious(0.02) | possibly_damaging(0.664) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ISLR | SNV | Missense_Mutation | rs376998994 | c.547G>A | p.Asp183Asn | p.D183N | O14498 | protein_coding | tolerated(0.69) | benign(0) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |